Related Experiment Video
Updated: Sep 18, 2025

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series
Nicky J Mehtani1,2, Janet Grochowski3, Anthonia Chimezie3
1Division of General Internal Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract:
Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9-38 weeks, highlighting its potential among adherence-challenged populations.
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Retroviruses
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

